The use of MCD as a model of NAFLD has revealed that Nrf2 deletion accelerates the onset of NAFLD and its progression to steatohepatitis [73, 74] while Nrf2 activation attenuates the progression of NAFLD [75]. This evidence concerns the gene NFE2L2 and metabolic dysfunction-associated steatotic liver disease.